Jarrod Winters United States

DermSpectra has developed an innovative high resolution full body imaging system designed to aid early detection of skin cancers and diseases, and revolutionize medical documentation.  The DermSpectra Automated Total Body Digital Skin Imaging (DSI) System fills a key technology gap in medical imaging, empowers physicians with an objective tool to accurately and efficiently detect and monitor skin and body changes over time and raises the bar for patient care.

Main Sector
Medtech Phase of Development
Technology Overview

The DermSpectra Total Body Digital Skin Imaging System is a proprietary solution that delivers patented high-resolution imaging, secure storage, and immediate viewing capabilities. With the most advanced level of precision in the market, DermSpectra sets the industry standard (definition, timing, lighting, image quality, data formats, secure storage, and interfaces) in digital skin imaging for dermatologists, plastic surgeons, cancer centers, clinical trials, general practitioners, and telemedicine services. The DermSpectra Total Body Digital Skin Imaging System solution strives to improve early detection of melanomas, skin cancers and treatment outcomes for patients and physicians by providing skin images that enable a comprehensive view and comparison of skin lesions and body changes over time.

Dermspectra LLC
Chief Operating Officer 

Neil Wyant

Everett Partners is the venture investing arm of an Akron Ohio based single family office.  The firm owns and manages an incubator in Israel and invests in companies in the life sciences space with a focus on technolog enabled, non-invasive medical devices.

Sector Interest
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Everett Partners
Managing Director